Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BAY 2395840 in Renal Impairment
NCT05406219Phase 1Withdrawn
- Sponsor
- Bayer
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of fulmetibant in diabetic neuropathy (3 arms), sponsored by Bayer. Primary endpoints: Area under the concentration vs. time curve from zero to infinity, Maximum observed drug concentration and 2 more. Planned start May 2023; status: withdrawn.
02
Drugs
fulmetibant
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT05406219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05406219.